Dr. Reddy's Labs gains on completing Phase 1 study of DRL_TC 0 19.12.2022 10:10 Business Standard Dr. Reddy's Laboratories rose 1.70% to Rs 4,382.40 after the pharmaceutical company said that its tocilizumab biosimilar candidate, DRL_TC has completed its primary and secondary endpoints in a Phase 1 study. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа Другие проекты от SMI24.net Музыкальные новости Агрегатор новостей 24СМИ
